Radan Bruha

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2358273/publications.pdf

Version: 2024-02-01

		361045	233125
55	2,102	20	45
papers	citations	h-index	g-index
57	57	57	2499
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology, 2006, 44, 1535-1542.	3.6	349
2	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	8.2	330
3	Late-Onset Wilson's Disease. Gastroenterology, 2007, 132, 1294-1298.	0.6	227
4	Alcoholic liver disease. World Journal of Hepatology, 2012, 4, 81.	0.8	145
5	Metabolomicâ€based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts. Hepatology Communications, 2018, 2, 807-820.	2.0	117
6	Longâ€ŧerm followâ€up of Wilson Disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver International, 2011, 31, 83-91.	1.9	114
7	Age and Sex but Not ATP7B Genotype Effectively Influence the Clinical Phenotype of Wilson Disease. Hepatology, 2019, 69, 1464-1476.	3.6	110
8	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology, 2020, 71, 1546-1558.	3.6	103
9	Pathogenesis of Wilson disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2017, 142, 43-55.	1.0	66
10	Sleep disorders in Wilson's disease. European Journal of Neurology, 2011, 18, 184-190.	1.7	56
11	Osteopontin – A potential biomarker of advanced liver disease. Annals of Hepatology, 2020, 19, 344-352.	0.6	43
12	Clinical trial: shortâ€term effects of combination of satavaptan, a selective vasopressin V ₂ receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia – a randomized, doubleâ€blind, placeboâ€controlled study. Alimentary Pharmacology and Therapeutics, 2010, 31, 834-845.	1.9	39
13	Use of Non-Invasive Parameters of Non-Alcoholic Steatohepatitis and Liver Fibrosis in Daily Practice - An Exploratory Case-Control Study. PLoS ONE, 2014, 9, e111551.	1.1	37
14	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31
15	Brain iron accumulation in Wilson's disease: A longitudinal imaging case study during anticopper treatment using 7.0T MRI and transcranial sonography. Journal of Magnetic Resonance Imaging, 2018, 47, 282-285.	1.9	29
16	Decreased serum antioxidant capacity in patients with Wilson disease is associated with neurological symptoms. Journal of Inherited Metabolic Disease, 2012, 35, 541-548.	1.7	28
17	Transjugular Renal Biopsy. Kidney and Blood Pressure Research, 2001, 24, 207-212.	0.9	26
18	Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World Journal of Gastroenterology, 2016, 22, 3441-3450.	1.4	25

#	Article	IF	CITATIONS
19	Safe use of ursodeoxycholic acid in a breast-feeding patient with primary biliary cirrhosis. Digestive and Liver Disease, 2010, 42, 911-912.	0.4	22
20	Associations of Brain Atrophy and Cerebral Iron Accumulation at MRI with Clinical Severity in Wilson Disease. Radiology, 2021, 299, 662-672.	3.6	22
21	Effect of Omegaâ€3 Polyunsaturated Fatty Acids on Lipid Metabolism in Patients With Metabolic Syndrome and NAFLD. Hepatology Communications, 2022, 6, 1336-1349.	2.0	22
22	Endoscopic variceal band ligation compared with propranolol for prophylaxis of first variceal bleeding. Annals of Hepatology, 2011, 10, 142-149.	0.6	20
23	Multiparametric Quantitative Brain MRI in Neurological and Hepatic Forms of Wilson's Disease. Journal of Magnetic Resonance Imaging, 2020, 51, 1829-1835.	1.9	19
24	Effect of carvedilol on portal hypertension depends on the degree of endothelial activation and inflammatory changes. Scandinavian Journal of Gastroenterology, 2006, 41, 1454-1463.	0.6	16
25	Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases. Parkinsonism and Related Disorders, 2016, 28, 87-93.	1.1	16
26	No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. Annals of Hepatology, 2011, 10, 445-451.	0.6	11
27	The efficacy of terlipressin in comparison with albumin in the prevention of circulatory changes after the paracentesis of tense ascites—a randomized multicentric study. Hepato-Gastroenterology, 2007, 54, 1930-3.	0.5	11
28	The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 442-448.	0.2	10
29	A bimodal pattern of the onset of COVID-19 related acute pancreatitis supports both the cytotoxic and immune-related pathogenesis – a systematic review. Scandinavian Journal of Gastroenterology, 2021, 56, 870-873.	0.6	9
30	Evaluation of hepatic fibrosis – access to non-invasive methods, national practice/guidelines in Central Europe. Clinical and Experimental Hepatology, 2016, 1, 12-15.	0.6	7
31	No association of promoter variations of HMOX1 and UGT1A1 genes with liver injury in chronic hepatitis C. Annals of Hepatology, 2011, 10, 445-51.	0.6	7
32	Double-blind randomized multicenter study comparing the efficacy and safety of 10-day to 5-day terlipressin treatment of bleeding esophageal varices. Hepato-Gastroenterology, 2009, 56, 390-4.	0.5	6
33	Association of Serum Bilirubin and Functional Variants of Heme Oxygenase 1 and Bilirubin UDP-Glucuronosyl Transferase Genes in Czech Adult Patients with Non-Alcoholic Fatty Liver Disease. Antioxidants, 2021, 10, 2000.	2.2	6
34	Non-Alcoholic Fatty Liver Disease. Vnitrni Lekarstvi, 2019, 65, 571-575.	0.1	4
35	Treatment of bleeding caused by liver cirrhosis-associated portal hypertension – update of Czech Society of Hepatology guidelines. Gastroenterologie A Hepatologie, 2017, 71, 105-116.	0.0	3
36	Flumazenil as a diagnostic test for latent hepatic encephalopathy. Journal of Hepatology, 1994, 20, 844.	1.8	2

#	Article	IF	CITATIONS
37	Gender Influences the Clinical Presentation of Wilson Disease (WD). Gastroenterology, 2011, 140, S-939.	0.6	2
38	Functional variants of <i>eNOS </i> hand <i>iNOS </i> genes have no relationship to the portal hypertension in patients with liver cirrhosis. Scandinavian Journal of Gastroenterology, 2013, 48, 592-601.	0.6	2
39	Acute responses of hepatic fat content to consuming fat, glucose and fructose alone and in combination in non-obese non-diabetic individuals with non-alcoholic fatty liver disease. Journal of Physiology and Pharmacology, 2021, 72, .	1.1	2
40	Serum markers in diagnostics of steatohepatitis. Vnitrni Lekarstvi, 2019, 65, 577-582.	0.1	2
41	Pancreatic Injury in Patients with SARS-Cov-2 (COVID-19) Infection: A Retrospective Analysis of CT Findings. Gastroenterology Research and Practice, 2021, 2021, 1-5.	0.7	2
42	Anemia as a predictor of response to antiviral therapy in chronic hepatitis C. Bratislava Medical Journal, 2013, 114, 213-217.	0.4	1
43	Osteopontin as a Biomarker in Liver Disease. Biomarkers in Disease, 2017, , 427-441.	0.0	1
44	Guidelines of the Czech Society of Hepatology for diagnosis and treatment of primary biliary cholangitis. Gastroenterologie A Hepatologie, 2018, 72, 109-118.	0.0	1
45	Guideline of the Czech Hepatology Society of the ÄŒLS JEP for diagnosis and treatment of non-alcoholic fatty liver disease. Gastroenterologie A Hepatologie, 2020, , .	0.0	1
46	Total Antioxidative Capacity in Serum Correlates With the Phenotypic Manifestation of Wilson Disease. Gastroenterology, 2011, 140, S-939.	0.6	0
47	ICU mortality of covid-19 patients - our experience. Vnitrni Lekarstvi, 2021, 67, e23-e27.	0.1	O
48	Clinically silent LINE 1 insertion in the PNPLA3 gene may impede genotyping of the p.I148M variant. Scientific Reports, 2021, 11, 20924.	1.6	0
49	Komentář k Äŀánku "ÚÄŀnnosÅ¥ a bezpeÄnosÅ¥ silymarÃnu u pacientov s chronickými chorobami peÄer multicentrická, prospektÃvna, otvorená klinická Å¡túdia IMHOTEP". Gastroenterologie A Hepatologie, 2014, 68, 462-464.	ne – 0.0	O
50	Functional variants of metalloproteinase MMP 1 and MMP 7 genes have no relationship to the severity of portal hypertension in patients with cirrhosis. Gastroenterologie A Hepatologie, 2015, 69, 116-120.	0.0	0
51	Screening of liver disease in patients with type 2 diabetes mellitus. Gastroenterologie A Hepatologie, 2015, 69, 365-367.	0.0	O
52	Osteopontin as a Biomarker in Liver Disease. Biomarkers in Disease, 2016, , 1-15.	0.0	0
53	Czech Society of Hepatology guidelines for diagnosis and treatment of acute porphyrias. Gastroenterologie A Hepatologie, 2017, 71, 101-104.	0.0	O
54	Rare manifestation of CMV infection - circular stenosis of the stomach. Vnitrni Lekarstvi, 2020, 66, e47-e50.	0.1	0

#	Article	IF	CITATIONS
55	Hepatic vein stenosis and inferior vena cava stenosis in a patient with chronic obstructive pulmonary disease. Hepato-Gastroenterology, 2005, 52, 1867-8.	0.5	0